Two therapies for immune-mediated inflammatory disease

Risankizumab vs upadacitinib: trial pipelines compared

A side-by-side view of the risankizumab and upadacitinib clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for risankizumab and 16+ for upadacitinib. Add up to three more drugs to widen the comparison.

risankizumab (16) vs upadacitinib (16)11 active2013–2033

Hide completed

risankizumabupadacitinib

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingNot yet recruitingCompleted

'13

'15

'17

'19

'21

'23

'25

'27

'29

'31

'33

risankizumab

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisP3

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentP3

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisP3

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisP2

FORTIFYP3

Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque PsoriasisP3

KEEPsAKE2P3

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or IxekizumabP3

SOPRANO-CDP4

PATHFINDERP4

AFFIRMP3

IMMpactfulP4

Target CDP2

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisP3

CHARGEP3

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisP2

upadacitinib

A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic TherapyP2

BALANCE-EXTENDP2

SELECT-NEXTP3

SELECT-EARLYP3

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic DermatitisP2

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic TherapyP3

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)P3

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)P3

Rising UpP3

SELECT-GCAP3

COVERP4

Level UpP3

Viti-UpP3

VICTRIVAP3

Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled StudyP3

UP-FOR-UP4

Upcoming readouts

11 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Head to head

Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.

risankizumab (Skyrizi)Immunology & inflammation

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Mar 2027

Next phase 3 readout

upadacitinib (Rinvoq)Immunology & inflammation

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Dec 2026

Next phase 3 readout

Key trials across both drugs

Top 16 registered phase 2–4 trials across risankizumab and upadacitinib, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.

Drug	Trial	Title	Phase	Status	Primary completion
risankizumab	NCT05928039	PATHFINDER: PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active…	Phase 4	Recruiting	Jul 2027
risankizumab	NCT05169593	SOPRANO-CD: Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biolog…	Phase 4	Recruiting	Oct 2027
upadacitinib	NCT07018206	UP-FOR-U: Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axi…	Phase 4	Not yet recruiting	May 2027
upadacitinib	NCT05080218	COVER: COVID-19 VaccinE Response in Rheumatology Patients	Phase 4	Completed	Apr 2024
risankizumab	NCT06333860	IMMpactful: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Trea…	Phase 4	Completed	Mar 2026
upadacitinib	NCT06227910	VICTRIVA: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease	Phase 3	Recruiting	Jun 2027
risankizumab	NCT07499232	CHARGE: A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Cro…	Phase 3	Recruiting	Nov 2028
upadacitinib	NCT07149467	Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory C…	Phase 3	Not yet recruiting	Dec 2026
risankizumab	NCT06063967	AFFIRM: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Ind…	Phase 3	Active, not recruiting	Mar 2027
upadacitinib	NCT06118411	Viti-Up: A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Ado…	Phase 3	Active, not recruiting	Mar 2028
risankizumab	NCT03105102	FORTIFY: A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease	Phase 3	Active, not recruiting	Feb 2029
risankizumab	NCT02684357	BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe C…	Phase 3	Completed	Dec 2016
risankizumab	NCT02684370	BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients Wit…	Phase 3	Completed	Dec 2016
upadacitinib	NCT02675426	SELECT-NEXT: A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Sta…	Phase 3	Completed	Apr 2017
risankizumab	NCT02672852	BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withd…	Phase 3	Completed	Aug 2017
upadacitinib	NCT02706873	SELECT-EARLY: A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adult…	Phase 3	Completed	Mar 2018

Track risankizumab and upadacitinib with ComplyRx

Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.

Track both drugs

FAQ

How do the risankizumab and upadacitinib clinical pipelines compare?: ClinicalTrials.gov currently lists 16+ phase 2–4 trials for risankizumab and 16+ for upadacitinib. The timeline above plots both side by side and refreshes daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
Can I add more drugs to the comparison?: Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.

Upcoming readouts

Head to head

Key trials across both drugs

Track risankizumab and upadacitinib with ComplyRx

Individual pipelines and other comparisons

FAQ

Be the first to access ComplyRx